Vera Therapeutics, Inc. Deferred Income Tax Expense (Benefit)
Vera Therapeutics, Inc. (VERA) reported Deferred Income Tax Expense (Benefit) of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-28.
Financial Statements › Cash Flow › Operating Activities
us-gaap:DeferredIncomeTaxExpenseBenefit · last filed 2025-02-28
- Vera Therapeutics, Inc. deferred income tax expense (benefit) for fiscal 2024 was $0.00.
- Vera Therapeutics, Inc. deferred income tax expense (benefit) for fiscal 2023 was $0.00.
- Vera Therapeutics, Inc. deferred income tax expense (benefit) for fiscal 2022 was $0.00.
- Vera Therapeutics, Inc. deferred income tax expense (benefit) for fiscal 2021 was $0.00.
| Period end | Deferred Income Tax Expense (Benefit) 12 month |
|---|---|
| 2024-12-31 | $0.00 10-K · filed 2025-02-28 |
| 2023-12-31 | $0.00 10-K · filed 2025-02-28 |
| 2022-12-31 | $0.00 10-K · filed 2024-03-27 |
| 2021-12-31 | $0.00 10-K · filed 2023-03-28 |
| 2020-12-31 | $0.00 10-K · filed 2022-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |